8-K: Werewolf Therapeutics Faces Nasdaq Delisting Warning

Werewolf Therapeutics, Inc. received a deficiency letter from Nasdaq due to its common stock trading below the $1.00 minimum bid price requirement.

Summary

• Werewolf Therapeutics, Inc. (HOWL) received a deficiency letter from the Nasdaq Stock Market, LLC on February 4, 2026.
• The notice indicates that the company's common stock bid price has closed below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1).
• The company has an initial period of 180 calendar days, expiring on August 3, 2026, to regain compliance.
• To regain compliance, the closing bid price of the common stock must be at least $1.00 per share for a minimum of 10 consecutive business days.
• There is no immediate effect on the listing of the company's common stock.
• If compliance is not regained within the initial period, the company may be eligible for an additional 180-calendar-day compliance period by transferring to the Nasdaq Capital Market, provided it meets other listing standards (except the Minimum Bid Requirement) and pays an application fee.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a significantly negative development, as a delisting notice signals underlying issues with investor confidence and potentially the company's long-term viability on a major exchange, despite the initial compliance period.

Positives

• The deficiency notice has no immediate effect on the listing of the company's common stock.
• The company has an initial 180-calendar-day period (until August 3, 2026) to regain compliance with the Minimum Bid Requirement.
• There is a potential for an additional 180-calendar-day compliance period if the company transfers to the Nasdaq Capital Market and meets other listing criteria.

Negatives

• The company's common stock bid price has fallen below the $1.00 minimum requirement for 30 consecutive business days, indicating significant investor concern.
• Failure to regain compliance could lead to the delisting of the company's common stock from the Nasdaq Global Select Market.
• There is no assurance that the company will be able to regain compliance with the Minimum Bid Requirement or that any appeal of a delisting determination would be successful.

Risks

• Failure to regain compliance with Nasdaq's Minimum Bid Requirement within the initial 180-calendar-day period or any subsequent extension.
• Potential delisting of the company's common stock from the Nasdaq Global Select Market, which could reduce liquidity and investor interest.
• Inability to meet the continued listing requirements for the Nasdaq Capital Market, should a transfer be pursued.
• Unsuccessful appeal to a Nasdaq Hearings Panel if a delisting determination is made.
• The company's inability to implement effective strategies to increase its stock price above the $1.00 threshold.

Future Outlook

The company intends to actively monitor the closing bid price of its common stock and evaluate available options to regain compliance with the Minimum Bid Requirement. However, there is no assurance that the company will be able to regain compliance.

Management Comments

• "The Company intends to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Requirement."
• "However, there can be no assurance that the Company will be able to regain compliance with the Bid Price Requirement."

Industry Context

StockSavvy.ai notes that receiving a Nasdaq deficiency letter for minimum bid price is a common challenge for smaller biotechnology companies, especially those in early development stages without significant revenue or late-stage clinical trial successes. Such notices often reflect broader market sentiment towards speculative growth stocks or specific company performance issues, potentially impacting investor confidence and access to capital.

Comparison to Industry Standards

• This situation is common among small-cap biotech firms, particularly those with market capitalizations below $500 million, which often struggle to maintain investor interest and stock price stability without major clinical milestones or partnerships.
• For example, companies like Athersys (ATHX) and Sorrento Therapeutics (SRNEQ) have faced similar delisting challenges due to low stock prices, often leading to reverse stock splits or eventual delisting.
• Maintaining a $1.00 bid price is a fundamental requirement for Nasdaq listing, and failure to do so places Werewolf Therapeutics in a category with other companies experiencing significant investor skepticism or operational difficulties.

Stakeholder Impact

• Shareholders face increased risk of delisting, which can lead to reduced liquidity, lower stock price, and potential loss of investment. Uncertainty regarding the company's future on a major exchange.
• Investors may view the company as higher risk, potentially impacting future investment decisions and access to capital.

Next Steps

• Werewolf Therapeutics must achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days by August 3, 2026, to regain compliance.
• If initial compliance is not met, the company may seek an additional 180-calendar-day period by transferring to the Nasdaq Capital Market, provided it meets other listing standards and pays an application fee.
• The company intends to actively monitor its stock price and evaluate options to regain compliance.
• If a delisting determination is made by the Staff, the company may appeal to a Hearings Panel, with its common stock expected to remain listed pending the Panel's decision.

Key Dates

Recommendation

The Nasdaq delisting notice due to sustained sub-$1.00 bid price signals significant investor concern and fundamental challenges for Werewolf Therapeutics. While there's a compliance period, the lack of assurance for regaining compliance, coupled with the potential for further market value erosion and reduced liquidity if delisted, makes the stock a high-risk proposition. A seasoned investor would likely consider exiting or significantly reducing exposure given the immediate regulatory pressure and the inherent uncertainty of a successful recovery.

Keywords

Werewolf Therapeutics, HOWL, Nasdaq, delisting, minimum bid price, compliance, biotechnology, regulatory notice, stock market, 8-K filing